Phase IB Trial of Induction Nivolumab or Nivolumab/Ipilimumab Prior to Concurrent Chemoradiation Plus Nivolumab in Patients With Operable Stage II/III Esophageal/ Gastroesophageal Junction Cancer
Phase of Trial: Phase I
Latest Information Update: 19 Jan 2019
At a glance
- Drugs Nivolumab (Primary) ; Relatlimab (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
- Focus Adverse reactions
- 19 Jan 2019 Results (n=16) presented at the 2019 Gastrointestinal Cancers Symposium
- 08 Jan 2019 Planned End Date changed from 1 Feb 2022 to 1 Feb 2025.
- 08 Jan 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Feb 2020.